

COVID-19 Monoclonal Antibodies & Administration Codes

Revised: January 1, 2023

Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS (See NOTE tab for additional instructions)

#	HCPCS	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
1	Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	Astra Zeneca	EVUSHELD 150-150MG/1.5ML Solution	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	12/8/2021	Report Q0220 with administration codes M0220, M0221
2	Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	AstraZeneca	Tixagev and cilgav, 600mg	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	2/24/2022	Report Q0221 with administration codes M0220, M0221
3	M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	Astra Zeneca	N/A	N/A	\$120.00	1	12/8/2021	Report M0220 with Q0220 & Q0221
4	M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Astra Zeneca	N/A	N/A	\$200.00	1	12/8/2021	Report M0221 with Q0220 & Q0221 for home administration
5	Q0222	Bebtelovimab, 175 mg	Eli Lilly	BEBTELOVIMA	00002-7589-01	\$0.00	1	2/11/2022	Report Q0222 with administration codes M0222, M0223
6	M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	Eli Lilly	N/A	N/A	\$280.00	1	2/11/2022	Report M0222 with Q0222
7	M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$440.00	1	2/11/2022	Report M0223 with Q0222
8	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
9	M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	Regeneron	N/A	N/A	\$360.00	1	6/8/2021	Report M0240 with Q0240
10	M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	Regeneron	N/A	N/A	\$600.00	1	7/30/2021	Report M0241 with Q0240 for home/residence administration
11	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 1200MG Solution	61755-0024-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 1200MG Solution	61755-0025-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0035-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0036-08	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244

COVID-19 Monoclonal Antibodies & Administration Codes									
Revised: January 1, 2023									
Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS (See NOTE tab for additional instructions)									
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0037-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0038-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML:120MG/ML Solution	61755-0042-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML:120MG/ML Solution	61755-0045-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
12	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML:120MG/ML Solution	61755-0042-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML:120MG/ML Solution	61755-0045-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
13	M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	Regeneron	N/A	N/A	\$360.00	1	12/1/2020	Report M0243 with Q0243/Q0244
14	M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Regeneron	N/A	N/A	\$600.00	1	5/6/2021	Report M0244 with Q0243 as well as Q0244 for home/residence administration
15	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	BAMLANIVIMAB 700MG/20ML Solution	00002-7910-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	ETESEVIMAB 35MG/ML Solution	00002-7950-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
16	M0245	Intravenous infusion, bamlanivimab and etesevimeb, includes infusion and post administration monitoring	Eli Lilly	N/A	N/A	\$360.00	1	2/9/2021	Report M0245 with Q0245
17	M0246	Intravenous infusion, bamlanivimab and etesevimeb, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$600.00		5/6/2021	Report M0246 with Q0245 for home/residence administration
18	Q0247	Sotrovimab, 500 mg	GSK	SOTROVIMAB 500MG/8ML Solution	00173-0901-86	\$0.00	1	5/26/2021	Report Q0247 with administration codes M0247, M0248
19	M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	GSK	N/A	N/A	\$360.00		5/26/2021	Report M0247 with Q0247
20	M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	GSK	N/A	N/A	\$600.00		5/26/2021	Report M0248 with Q0247 for home/residence administration
21	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 20MG/ML Solution	50242-0135-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 200MG/10ML Solution	50242-0136-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 400MG/20ML Solution	50242-0137-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
22	M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0249 with Q0294 - 1st dose
23	M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0250 with Q0294 - 2nd dose